BRCA Germline Mutations in Jewish Patients With Pancreatic Adenocarcinoma
- 20 January 2009
- journal article
- surgical oncology
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (3), 433-438
- https://doi.org/10.1200/jco.2008.18.5546
Abstract
Purpose The prognostic significance of germline BRCA1 and BRCA2 mutations in Jewish patients with pancreatic adenocarcinoma (PAC) is unknown. Our objective was to define the prevalence of BRCA1 and...Keywords
This publication has 53 references indexed in Scilit:
- Combination therapy of poly (ADP‐ribose) polymerase inhibitor 3‐aminobenzamide and gemcitabine shows strong antitumor activity in pancreatic cancer cellsJournal of Gastroenterology and Hepatology, 2007
- BRCA Mutation Frequency and Penetrance: New Data, Old DebateJNCI Journal of the National Cancer Institute, 2006
- BRCA2-deficient CAPAN-1 cells are extremely sensitive to the inhibition of poly (ADP-ribose) polymerase: An issue of potencyCancer Biology & Therapy, 2005
- Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategyNature, 2005
- New BRCA2 mutation in an Ashkenazi Jewish family with breast and ovarian cancerThe Lancet, 1997
- The Risk of Cancer Associated with Specific Mutations ofBRCA1andBRCA2among Ashkenazi JewsNew England Journal of Medicine, 1997
- Pancreatic Cancer and Occupational ExposuresEpidemiology, 1995
- The gene for hereditary breast-ovarian cancer, BRCA1, maps distal to EDH17B2 in chromosome region 17q12–q21Human Molecular Genetics, 1994
- Neoplastic diseases in families of breast cancer patients.Journal of Medical Genetics, 1994
- Mutation in the DNA mismatch repair gene homologue hMLH 1 is associated with hereditary non-polyposis colon cancerNature, 1994